tert-butyl 4-((4-benzylmorpholin-2-yl)methyl)piperazine-1-carboxylate | 635698-80-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-((4-benzylmorpholin-2-yl)methyl)piperazine-1-carboxylate
• 英文别名: tert-butyl 4-(4-benzylmorpholin-2-ylmethyl)piperazinecarboxylate；tert-butyl 4-[(4-benzylmorpholin-2-yl)methyl]piperazine-1-carboxylate
• CAS: 635698-80-5
• 化学式: C₂₁H₃₃N₃O₃
• 分子量: 375.511
• InChiKey: NRUHHOVQAIAJLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  45.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-((4-benzylmorpholin-2-yl)methyl)piperazine-1-carboxylate 在 三氟乙酸 、 potassium carbonate 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 4-benzyl-2-(piperazin-1-ylmethyl)morpholine
  参考文献：
  名称：

  WO2008/145681

  摘要：

  公开号：
• 作为产物：
  描述：

  (4-苄基吗啉-2-基)甲醇 在 三乙酰氧基硼氢化钠 、 戴斯-马丁氧化剂 、 溶剂黄146 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.25h， 生成 tert-butyl 4-((4-benzylmorpholin-2-yl)methyl)piperazine-1-carboxylate
  参考文献：
  名称：

  WO2008/145681

  摘要：

  公开号：

文献信息

• BICYCLIC PYRIMIDINE DERIVATIVES
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1552842A1

  公开（公告）日：2005-07-13

  [wherein m and n may be the same or different and each represents an integer of 1 to 3 wherein m + n is 4 or less; R1 represents NR4R5 (wherein R4 and R5 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl or the like); R2 represents the above Formula (II), Formula (IV) or the like; A represents a single bond, -C(=O)-, -SO2-, -OC(=O)- or the like; and R3 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl or the like] Bicyclic pyrimidine derivatives represented by the above Formula (I), or quaternary ammonium salts thereof, or pharmaceutically acceptable salts thereof, or the like, are provided. These have anti-inflammatory activities or modulation activities on the functions of TARC and/or MDC and are useful for treating and/or preventing a disease which is related to T cells, such as an allergic disease, an autoimmune disease or transplant rejection.

  提供上述公式（I）所代表的双环嘧啶衍生物，或其季铵盐，或其药用盐等。这些化合物具有抗炎活性或对TARC和/或MDC功能的调节活性，并且可用于治疗和/或预防与T细胞相关的疾病，如过敏性疾病、自身免疫疾病或移植排斥等。
• Bicyclic pyrimidine derivatives
  申请人：Arai Hitoshi

  公开号：US20070037834A1

  公开（公告）日：2007-02-15

  [wherein m and n may be the same or different and each represents an integer of 1 to 3 wherein m+n is 4 or less; R 1 represents —NR 4 R 5 (wherein R 4 and R 5 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl or the like); R 2 represents the above Formula (II), Formula (IV) or the like; A represents a single bond, —C(═O)—, —SO 2 —, —OC(═O)— or the like; and R 3 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl or the like] Bicyclic pyrimidine derivatives represented by the above Formula (I), or quaternary ammonium salts thereof, or pharmaceutically acceptable salts thereof, or the like, are provided. These have anti-inflammatory activities or modulation activities on the functions of TARC and/or MDC and are useful for treating and/or preventing a disease which is related to T cells, such as an allergic disease, an autoimmune disease or transplant rejection.

  提供上述公式（I）所代表的双环嘧啶衍生物，其中m和n可以相同或不同，每个表示1至3的整数，其中m+n小于等于4；R1表示—NR4R5（其中R4和R5可以相同或不同，每个表示氢原子，取代或未取代的低碳基，取代或未取代的芳基烷基或类似物）；R2表示上述公式（II），公式（IV）或类似物；A表示单键，—C（═O）—，—SO2—，—OC（═O）—或类似物；R3表示取代或未取代的低碳基，取代或未取代的环烷基，取代或未取代的芳基烷基或类似物。还提供了上述公式（I）所代表的四元铵盐或药学上可接受的盐或类似物。这些化合物具有抗炎活性或对TARC和/或MDC功能的调节活性，并且用于治疗和/或预防与T细胞相关的疾病，例如过敏性疾病，自身免疫性疾病或移植排斥。
• CCR2 Receptor Antagonists and Uses Thereof
  申请人：Ebel Heiner

  公开号：US20100204209A1

  公开（公告）日：2010-08-12

  The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.

  本发明涉及新型CCR2（CC趋化因子受体2）拮抗剂及其用于提供治疗疾病和病症的药物，特别是用于治疗肺部疾病，如哮喘和COPD。
• CCR2 receptor antagonists and uses thereof
  申请人：Ebel Heiner

  公开号：US08653262B2

  公开（公告）日：2014-02-18

  The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.

  本发明涉及新的CCR2（CC趋化因子受体2）拮抗剂及其用途，用于提供治疗疾病和病症的药物，特别是用于治疗肺部疾病，如哮喘和COPD。
• CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2155689A2

  公开（公告）日：2010-02-24